A phase II trial of durvalumab and tremelimumab in metastatic, non ‐urothelial carcinoma of the urinary tract

ConclusionsIn a poor prognosis cohort of patients with non ‐UC, durvalumab and tremelimumab lacked clinical activity while demonstrating a manageable safety profile.

Source: Cancer Medicine - December 31, 2020 Category: Cancer & Oncology Authors: Michal Sarfaty, Karissa Whiting, Min Yuen Teo, Chung ‐Han Lee, Vanessa Peters, Jennifer Durocher, Ashley M. Regazzi, Asia S. McCoy, Grace Hettich, Achim A. Jungbluth, Hikmat Al‐Ahmadie, Irina Ostrovnaya, Joshua Chaim, Dean F. Bajorin, Jo Tags: ORIGINAL RESEARCH Source Type: research